

Learner Notification

MED Learning Group

The DETECT Initiative in Early Alzheimer's Disease: Optimizing Collaboration and Multidisciplinary Care to Facilitate Timely Diagnosis

Various Dates: December 16, 2022 – July 31, 2023

Online

Acknowledgement of Financial Commercial Support

Eli Lilly

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate the burden of Alzheimer's disease (AD), including the process of prolonged decline in cognitive function.
2. Use cognitive assessments, biomarkers and imaging to distinguish between normal aging and cognitive impairment.
3. Select and use the best therapeutic options for patients with AD based on up-to-date clinical data on established and emerging disease modifying therapies.
4. Employ best practices for multidisciplinary care coordination, workflows, and best practices for referral of patients.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Douglas	Cox	NA
Lisa	Crenshaw	NA
Daniel	DaSilva	NA
Brad	Dickerson	Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Wave Lifesciences: Consultant; Oxford University press, Cambridge University press, Elsevier: Royalties
Matthew	Frese	NA
Christina	Gallo	NA
Debra	Gordon	NA
Morgan	Kravarik	NA
Lauren	Welch	NA
David A.	Wolk	Eli Lilly, CE Healthcare, Qynapse: Consultant; Biogen: Site-PI; Functional Neuromodulation: Data and Safety Monitoring Board

Questions? Email Certificate@AmedcoEmail.com